B4813

BGP-15

≥98% (HPLC)

• Fórmula empírica (notación de Hill): C₁₄H₂₂N₄O₂· 2HCl
• Número CAS: 66611-37-8
• Peso molecular: 351.27
• NACRES: NA.77
• PubChem Substance ID: 329773244
• UNSPSC Code: 12352200
• MDL number: MFCD21603901
• Assay: ≥98% (HPLC)
• Form: solid

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• solubility: deionized water: 28 mg/mL
• storage temp.: −20°C
• SMILES string: Cl.Cl.N\C(=N/OCC(O)CN1CCCCC1)c2cccnc2
• InChI: 1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
• InChI key: ISGGVCWFTPTHIX-UHFFFAOYSA-N

Descripción

General description

BGP-15 is a hydroxylamine derivative, which has cytoprotective and neuroprotective properties. It reduces phospho- c-Jun N-terminal kinase (pJNK) and p38 stress signalling. BGP-15 also stimulates non-specific serine/threonine protein kinase (AKT) and insulin-like growth factor 1 receptor (IGFR1) protective signalling. BGP-15 functions as an insulin sensitizer in an olanzapine-induced metabolic disorder. It protects cells against cell death and enhances the expression of heat shock protein (HSP). BGP-15 might be used to treat heart failure (HF) and atrial fibrillation (AF).[1]

Application

BGP-15 has been used to study its influence on proteasomal degradation of missense dystrophins.

Biochem/physiol Actions

BGP-15 is PARP inhibitor, HSP72 activator.

BGP-15 is PARP inhibitor, HSP72 activator.

Información de seguridad

• pictograms: GHS06
• signalword: Danger
• hcodes: H301
• pcodes: P264 - P270 - P301 + P310 - P405 - P501
• Hazard Classifications: Acute Tox. 3 Oral
• Clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable